Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Detailed Structure and Function of Lymph Nodes01:23

Detailed Structure and Function of Lymph Nodes

Lymph nodes are bean-shaped structures that cluster along the lymphatic vessels in the inguinal, axillary, and cervical regions. Each node is divided into compartments by a capsule that extends trabeculae inward.
From a histological perspective, lymph nodes can be split into two main areas: the superficial cortex and the deep medulla. The outer cortex is populated by dendritic cells, macrophages, and B lymphocytes, which are densely packed into follicles. When these B-lymphocytes are presented...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

European journal of nuclear medicine and molecular imaging·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

The Lancet. Haematology·2026
Same author

Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma.

Global & regional health technology assessment·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Diffuse large B-cell lymphoma.

Maurizio Martelli1, Andrés J M Ferreri, Claudio Agostinelli

  • 1Division of Hematology, University La Sapienza, Rome, Italy.

Critical Reviews in Oncology/Hematology
|February 5, 2013
PubMed
Summary
This summary is machine-generated.

Diffuse large B-cell lymphoma (DLBCL) is a common adult cancer. Treatment varies by prognosis, with rituximab plus CHOP chemotherapy as standard, and stem cell transplant for relapsed cases. Novel agents are under investigation.

Keywords:
Aggressive lymphomasAutologous transplantationCHOPDiffuse large B-cell lymphomaRituximab

Related Experiment Videos

Last Updated: May 14, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in adults.
  • DLBCL exhibits significant biological and clinical heterogeneity, with some cases classified as DLBCL, not otherwise specified (NOS).
  • Prognosis and treatment strategies are influenced by disease stage, patient age, and prognostic indices like the International Prognostic Index (IPI).

Purpose of the Study:

  • To review the current understanding of DLBCL, including its classification, clinical presentation, and prognostic factors.
  • To outline the standard first-line and salvage treatment approaches for DLBCL.
  • To highlight emerging therapeutic strategies and novel agents being investigated for DLBCL treatment.

Main Methods:

  • Review of existing literature on DLBCL classification, clinical behavior, and treatment outcomes.
  • Analysis of prognostic indices (IPI, aaIPI) and their role in treatment stratification.
  • Summary of current standard therapies, including immunochemotherapy and autologous stem cell transplantation (ASCT).

Main Results:

  • DLBCL is aggressive but potentially curable, with cure rates varying based on disease extent and patient risk factors.
  • Rituximab combined with CHOP chemotherapy is the standard first-line treatment.
  • High-dose chemotherapy with ASCT is recommended for relapsed disease, not as upfront therapy for most high-risk patients.
  • Consolidation radiotherapy is reserved for bulky disease achieving complete remission.
  • CNS prophylaxis is indicated for high-risk patients.
  • Novel agents including lenalidomide, mTOR inhibitors, proteasome inhibitors, HDAC inhibitors, and anti-angiogenic agents are under investigation.

Conclusions:

  • DLBCL management requires tailored treatment based on prognostic factors and disease characteristics.
  • While standard therapies offer good outcomes, novel agents are crucial for improving results in refractory or relapsed cases.
  • Ongoing research into novel agents and treatment strategies holds promise for enhancing DLBCL patient survival and quality of life.